Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

556
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
556
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

21
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
21
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

581
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
581
Drug Therapy01:28

Drug Therapy

75
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
75

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Cellular Senescence as a Therapeutic Strategy to Attenuate Pulmonary Fibrosis Associated with Metabolic Syndrome.

Aging and disease·2026
Same author

Hybrid Laparoscopic-Endoscopic Partial Jejunal Diversion with Magnetic Anastomosis in Obesity and Type 2 Diabetes: Durable 3-Year Metabolic Results.

Endoscopy international open·2026
Same author

Correction: Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Reviews in endocrine & metabolic disorders·2026
Same author

Magnetic vs stapled technique in jejuno-ileal bipartition: one-year outcomes.

Surgical endoscopy·2026
Same author

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

The lancet. Diabetes & endocrinology·2026
Same author

Multimodal prehabilitation in patients with advanced ovarian cancer.

Gynecologic oncology·2026

Related Experiment Video

Updated: Jul 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

525

Obesity pharmacotherapy - update 2023.

Martin Haluzík, Dana Müllerová, Petr Sucharda

    Casopis Lekaru Ceskych
    |May 15, 2023
    PubMed
    Summary

    Effective anti-obesity medications are available but often unaffordable due to lack of insurance coverage. Reimbursement is crucial for managing obesity and its costly health complications.

    Keywords:
    antiobesityantiobesity drugscomplications of obesitydiabetesheart failureobesityobesity complicationspharmacotherapy

    More Related Videos

    Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
    13:09

    Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

    Published on: July 31, 2021

    3.8K
    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
    06:28

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

    Published on: April 28, 2023

    901

    Related Experiment Videos

    Last Updated: Jul 30, 2025

    An Acupoint Catgut-embedding Therapy for Treating Obesity
    04:50

    An Acupoint Catgut-embedding Therapy for Treating Obesity

    Published on: April 4, 2025

    525
    Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
    13:09

    Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

    Published on: July 31, 2021

    3.8K
    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
    06:28

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

    Published on: April 28, 2023

    901

    Area of Science:

    • Endocrinology
    • Public Health
    • Pharmacology

    Background:

    • Obesity prevalence and complications necessitate improved treatment strategies.
    • Current lifestyle modifications for obesity often lack long-term success.
    • Pharmacotherapy is emerging as a vital component of comprehensive obesity management.

    Purpose of the Study:

    • To review current anti-obesity pharmacotherapy options.
    • To assess the long-term efficacy and safety of obesity medications.
    • To discuss the health-economic implications of limited access to these treatments.

    Main Methods:

    • Literature review of current obesity pharmacotherapy.
    • Analysis of studies on long-term drug efficacy and safety.
    • Evaluation of health-economic consequences of treatment access.

    Main Results:

    • Effective and safe anti-obesity drugs exist but face limited insurance coverage.
    • High treatment costs prevent long-term adherence for many patients.
    • Lack of access leads to increased prevalence of costly obesity-related diseases.

    Conclusions:

    • Partial health insurance reimbursement for anti-obesity drugs is necessary.
    • Reimbursement would improve patient outcomes and reduce long-term healthcare costs.
    • Evidence-based pharmacotherapy offers a cost-effective approach to obesity management.